Cord blood CAR-T: a new hope for adults with B-Cell leukemia?

NCT ID NCT07256353

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) using immune cells from donated umbilical cord blood that are engineered to attack cancer cells (UCAR-T). The study will enroll 50 participants to check safety, find the best dose, and see if the treatment can clear leukemia from the bone marrow. Participants will receive the UCAR-T cells by IV and be closely monitored for side effects and response for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

allogeneic umbilical cord blood-derived CAR-T cells (UCAR-T)

What this could lead to

If it works, this could provide a safer, more accessible treatment option for adults with B-cell acute lymphoblastic leukemia who have limited alternatives.

What could go wrong

This is a very early (Phase 1) trial with only 50 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome or organ damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell adult acute lymphocytic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The General Hospital of Western Theater Command

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••